Brian S Bull

6436655, Aug 20, 2002

Sep 2, 1999

09/388796

Brian S. Bull - Loma Linda CA
Ralph A. Korpman - Nashville TN

Medical Devices Corporation - Nashville TN

C12Q 156

435 13, 530358

A method for determining the existence and the amount of soluble fibrin contained in a specimen fluid is provided. The method includes the steps of precipitating soluble fibrin out of the opaque specimen fluid, aggregating the soluble fibrin precipitates in a limited region of a transparent container so as to render the precipitates optically detectable in the opaque specimen fluid, and optically detecting the precipitates. The amount of soluble fibrin may be determined by measuring the time from the addition of the precipitating regent to the detection of the soluble fibrin precipitates. Methods of the present invention allow one to measure soluble fibrin in whole blood, and therefore render the test useful in the operating room under conditions of major surgery and in the presence of severe trauma wherein DIC is likely to supervene.

6777199, Aug 17, 2004

Apr 29, 2002

10/136037

Brian S. Bull - Loma Linda CA
Ralph A. Korpman - Nashville TN
Karen L. Hay - Redlands CA

Medical Devices Corporation - Nashville TN

C12Q 156

435 13, 530381, 422 73

A method for determining the existence and the amount of soluble fibrin contained in a specimen fluid is provided. The method includes the steps of precipitating soluble fibrin out of the opaque specimen fluid, aggregating the soluble fibrin precipitates in a limited region of a transparent container so as to render the precipitates optically detectable in the opaque specimen fluid, and optically detecting the precipitates. The amount of soluble fibrin may be determined by measuring the time from the addition of the precipitating regent to the detection of the soluble fibrin precipitates. Methods of the present invention allow one to measure soluble fibrin in whole blood, and therefore render the test useful in the operating room under conditions of major surgery and in the presence of severe trauma wherein DIC is likely to supervene.

7264579, Sep 4, 2007

May 27, 2004

10/856636

Brian S. Bull - Loma Linda CA, US

A63B 21/02

482121, 482126

A device and method for preventing the damage underlying lateral epicondylitis (tennis elbow) or medial epicondylitis (golfer's elbow), or both lateral epicondylitis (tennis elbow) and medial epicondylitis (golfer's elbow), or for treating the damage underlying lateral epicondylitis (tennis elbow) or medial epicondylitis (golfer's elbow), or both lateral epicondylitis (tennis elbow) and medial epicondylitis (golfer's elbow). The device comprises a central support (), and one or more than one extension-adduction apparatus () or one or more than one flexion-abduction apparatus (), or both one or more than one extension-adduction apparatus () and one or more than one flexion-abduction apparatus ().

20110237409, Sep 29, 2011

Mar 11, 2011

13/045978

Brian Stanley Bull - Loma Linda CA, US

A63B 21/02

482126

An exercise device for strengthening the small muscles and tendons that stabilize the inner and outer parts of the elbow includes a hollow outer housing, an inner housing adapted to slide into and out of the hollow outer housing, a plurality of elastic bands placed inside the interior of the inner housing, a slot located along the sidewalls of the hollow outer housing, a connector secured to the inner housing and passing through the slot of the hollow outer housing, and the inner housing is adapted to slide from a retracted position to an extended position against the resistance provided by one or more elastic bands.

20110301180, Dec 8, 2011

Apr 25, 2011

13/093825

James P. Collman - Stanford CA, US
Paul Clifford Herrmann - Loma Linda CA, US
David Alvin Tyvoll - La Jolla CA, US
Richard Decreau - Cedex, FR
Brian Stanley Bull - Loma Linda CA, US
Christopher Jeffrey Barile - San Carlos CA, US

Stanford University - Palo Alto CA

A61K 31/4192
C07D 277/02
C07F 9/54
C07D 257/04
C07D 277/40
C07D 277/22
C07D 277/24
C07D 209/12
C07D 233/84
C07D 239/26
C07D 339/04
A61K 31/41
A61K 31/426
A61K 31/4164
A61K 31/404
A61K 31/505
A61K 31/385
A61P 7/02
A61P 9/10
A61P 9/04
A61P 3/00
A61P 9/12
A61P 3/10
A61P 9/00
C07D 249/06

514256, 548255, 548146, 548119, 548253, 548250, 548251, 548254, 548252, 5483241, 548199, 548202, 548203, 548491, 5483251, 544242, 549 39, 514359, 514381, 514370, 514365, 514392, 514415, 514398, 514440

It has been discovered that inhibiting mitochondrial respiration in platelets reduces platelet activation or platelet aggregation. Certain heterocyclic compounds significantly reduced one or more platelet functions including clumping, sticking or platelet-stimulated clotting. Thus diseases or disorders mediated by inappropriately high levels of platelet activation or platelet aggregation can be treated by administering a therapeutically effective amount of a heterocyclic compound or nonheterocyclic mitochondrial inhibitor that significantly reduces one or more platelet functions including clumping, sticking or platelet-stimulated clotting, preferably in a reversible manner.

55941648, Jan 14, 1997

Jul 12, 1994

8/270681

Brian S. Bull - Loma Linda CA

G01N 3349

73 6166

An apparatus and method for rapid determination of erythrocyte sedimentation rates for a blood specimen (29) which can be linearly transposed to Westergren sedimentation rates. The method includes the steps of inducing accelerated rouleaux formation in the specimen (29) in an amount sufficient to begin settling at substantially the decantation rate for the specimen. In one embodiment a structure (27) which produces a very thin cross-sectional region (37) of the specimen (29) inside the lumen (23) of a specimen container (21) is provided to accelerate rouleaux formation. In an alternative embodiment (120), accelerated rouleaux formation is accomplished using a centrifuge (122). A third embodiment employs a movable rod (223) mounted inside the specimen tube (221) to induce accelerated rouleaux formation. All embodiments of the process next employ gravity settling the specimen in a near horizontal oriented container (21, 121, 221). Thereafter, the amount of settling occurring is determined.

55061451, Apr 9, 1996

Dec 2, 1994

8/348345

Brian S. Bull - Loma Linda CA
Robert A. Levine - Guilford CT
Stephen C. Wardlaw - Old Saybrook CT

G01N 3386
G01N 3372

436 69

Useful information about a subject's level of systemic inflammation is obtained by quantitatively measuring the amount of fibrinogen and the hematocrit and or hemoglobin in the subject's whole blood. The fibrinogen measurement, when combined with an hematocrit or hemoglobin measurement, provides a systemic Inflammation Index value for the donor. The method is not affected by blood variables which are not related to the presence of inflammation, which blood variables are known to invalidate an erythrocyte sedimentation rate, which is the most frequently used blood test for detecting systemic inflammation in humans.

58441280, Dec 1, 1998

Jul 28, 1997

8/901593

Brian S. Bull - Loma Linda CA

G01N 3316
B01F 1308
G01D 0532

73 6166

An apparatus and method for rapid determination of erythrocyte sedimentation rates for a blood specimen (29) which can be linearly transposed to Westergren sedimentation rates. The method includes the steps of inducing accelerated rouleaux formation in the specimen (29) in an amount sufficient to begin settling at substantially the decantation rate for the specimen. In one embodiment a structure (27) which produces a very thin cross-sectional region (37) of the specimen (29) inside the lumen (23) of a specimen container (21) is provided to accelerate rouleaux formation. In an alternative embodiment (120), accelerated rouleaux formation is accomplished using a centrifuge (122). A third embodiment employs a movable rod (223) mounted inside the specimen tube (221) to induce accelerated rouleaux formation. All embodiments of the process next employ gravity settling the specimen in a near horizontal oriented container (21, 121, 221). Thereafter, the amount of settling occurring is determined.